Takeaway
Loss of transmembrane protein 106B biological function leads to myelination deficits in a genetic mouse model of frontotemporal dementia.
Why this matters
There is increasing interest in the feasibility of transmembrane protein 106B as a potential therapeutic target in frontotemporal dementia. These novel findings provide important information about the impact of lowering these protein levels in a unique mouse model.